Literature DB >> 20857491

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

Dung T Le1, Brian H Ladle, Timothy Lee, Vivian Weiss, Xiaosai Yao, Ashley Leubner, Todd D Armstrong, Elizabeth M Jaffee.   

Abstract

The composition of tumor infiltrating lymphocytes (TIL) is heterogeneous. In addition, the ratio of various subpopulations in the tumor microenvironment is highly dependent on the nature of the host's immune response. Here, we characterize Foxp3-expressing CD8(+) T cells in the tumor that demonstrate effector function and accumulate in the context of an effective anti-tumor response. CD8(+) Foxp3(+) T cells are induced in TIL in regressing tumors of FVB/N mice treated with a GM-CSF secreting HER-2/neu targeted whole cell vaccine. Foxp3 expression in tumor antigen-specific CD8 T cells is restricted to the tumor microenvironment and influenced by cues in the tumor. Interestingly, Foxp3(+) and Foxp3(-) CD8(+) T cells have similar IFN-γ production and antigen-specific degranulation after stimulation with RNEU(420-429) , the immunodominant HER-2/neu (neu) epitope in this model. Adoptive transfer studies, using RNEU((420-429)) -specific effector T cells into neu-N mice (a model that results in immune tolerance to neu), confirm that CD8(+) Foxp3(+) T cells are present in tumors only if there is an existing pool of tumor-rejecting effector T cells. CD8(+) Foxp3(+) TILs mark the presence of tumor-rejecting antigen-specific T cells and their accumulation serves as a marker for an effective T cell response.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20857491      PMCID: PMC3064958          DOI: 10.1002/ijc.25693

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.

Authors:  Michael R Betts; Jason M Brenchley; David A Price; Stephen C De Rosa; Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

2.  Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Authors:  Anne M Ercolini; Jean-Pascal H Machiels; Yi Cheng Chen; Jill E Slansky; Martin Giedlen; R Todd Reilly; Elizabeth M Jaffee
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

3.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

Authors:  R T Reilly; M B Gottlieb; A M Ercolini; J P Machiels; C E Kane; F I Okoye; W J Muller; K H Dixon; E M Jaffee
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

4.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

5.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

6.  Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.

Authors:  Kimberly A Shafer-Weaver; Michael J Anderson; Katherine Stagliano; Anatoli Malyguine; Norman M Greenberg; Arthur A Hurwitz
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

7.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors:  Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

8.  CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

Authors:  Yukiko Kiniwa; Yoshihiro Miyahara; Helen Y Wang; Weiyi Peng; Guangyong Peng; Thomas M Wheeler; Timothy C Thompson; Lloyd J Old; Rong-Fu Wang
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

9.  A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.

Authors:  Elizabeth A Manning; John G M Ullman; James M Leatherman; Justin M Asquith; Timothy R Hansen; Todd D Armstrong; Daniel J Hicklin; Elizabeth M Jaffee; Leisha A Emens
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.

Authors:  Sergio A Quezada; Karl S Peggs; Tyler R Simpson; Yuelei Shen; Dan R Littman; James P Allison
Journal:  J Exp Med       Date:  2008-08-25       Impact factor: 14.307

View more
  11 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 2.  The regulation of immune tolerance by FOXP3.

Authors:  Ling Lu; Joseph Barbi; Fan Pan
Journal:  Nat Rev Immunol       Date:  2017-07-31       Impact factor: 53.106

3.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Authors:  Dipongkor Saha; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

4.  PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.

Authors:  Adam A Kraya; Kara N Maxwell; Monika A Eiva; Bradley Wubbenhorst; John Pluta; Michael Feldman; Anupma Nayak; Daniel J Powell; Susan M Domchek; Robert H Vonderheide; Katherine L Nathanson
Journal:  JCO Precis Oncol       Date:  2022-02

5.  Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance.

Authors:  Emily L Hopewell; Weipeng Zhao; William J Fulp; Crystina C Bronk; Alexis S Lopez; Michael Massengill; Scott Antonia; Esteban Celis; Eric B Haura; Steven A Enkemann; Dung-Tsa Chen; Amer A Beg
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

6.  Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.

Authors:  Sneha Berry; Nicolas A Giraldo; Benjamin F Green; Alexander S Szalay; Janis M Taube; Tricia R Cottrell; Julie E Stein; Elizabeth L Engle; Haiying Xu; Aleksandra Ogurtsova; Charles Roberts; Daphne Wang; Peter Nguyen; Qingfeng Zhu; Sigfredo Soto-Diaz; Jose Loyola; Inbal B Sander; Pok Fai Wong; Shlomit Jessel; Joshua Doyle; Danielle Signer; Richard Wilton; Jeffrey S Roskes; Margaret Eminizer; Seyoun Park; Joel C Sunshine; Elizabeth M Jaffee; Alexander Baras; Angelo M De Marzo; Suzanne L Topalian; Harriet Kluger; Leslie Cope; Evan J Lipson; Ludmila Danilova; Robert A Anders; David L Rimm; Drew M Pardoll
Journal:  Science       Date:  2021-06-11       Impact factor: 47.728

7.  Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer.

Authors:  Paul H van der Horst; Yongyi Wang; Ingrid Vandenput; Liesbeth C Kühne; Patricia C Ewing; Wilfred F J van Ijcken; Marten van der Zee; Frederic Amant; Curt W Burger; Leen J Blok
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

8.  Quantitative Assessment of the Immune Microenvironment in Patients With Iatrogenic Laryngotracheal Stenosis.

Authors:  Ruth J Davis; Ioan Lina; Benjamin Green; Elizabeth L Engle; Kevin Motz; Dacheng Ding; Janis M Taube; Alexander Gelbard; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2020-12-08       Impact factor: 5.591

9.  Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.

Authors:  A M Heeren; J Rotman; A G M Stam; N Pocorni; A A Gassama; S Samuels; M C G Bleeker; C H Mom; H J M A A Zijlmans; G G Kenter; E S Jordanova; T D de Gruijl
Journal:  J Immunother Cancer       Date:  2019-02-12       Impact factor: 13.751

10.  Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

Authors:  Maria Libera Ascierto; Michael O Idowu; Yingdong Zhao; Hanif Khalak; Kyle K Payne; Xiang-Yang Wang; Catherine I Dumur; Davide Bedognetti; Sara Tomei; Paolo A Ascierto; Anil Shanker; Harry D Bear; Ena Wang; Francesco M Marincola; Andrea De Maria; Masoud H Manjili
Journal:  J Transl Med       Date:  2013-06-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.